摘要
目的研究胃癌患者新辅助化疗前血小板水平对疗效的预测价值。方法回顾性分析2012年6月至2014年6月间在解放军总医院行胃癌新辅助化疗患者122例。患者行奥沙利铂联合替吉奥方案新辅助化疗2～4个周期，之后行根治性胃癌切除手术加D，淋巴结清扫。依据1．1版实体瘤疗效评价标准综合评价肿瘤对化疗的反应，分析新辅助化疗前不同血小板水平与疗效的相关性。结果本组122例新辅助化疗疗效的评估：完全缓解20例（16．4％），部分缓解59例（48．4％），疾病稳定40例（32．8％），疾病进展3例（2．5％），总体有效率为64．8％，疾病控制率为97．5％。新辅助化疗前血小板〉300x10’／L（19例）和血小板≤300×10^9／L（103例）患者的总体有效率分别为36．8％、69．9％，差异有统计学意义（x2=7．682，P=0．008）。结论胃癌患者新辅助化疗前血小板水平与疗效有关，新辅助化疗前血小板水平越低则有效率越高。
Objective To study the prognostic value of platelet count in gastric cancer neoadjuvant chemotherapy. Methods This retrospective study consisted of 122 patients with gastric cancer who underwent neoadjuvant chemotherapy at Department of General Surgery, Chinese PLA General Hospital from June 2012 to June 2014. Patients received oxalipatin and S-1 as neoadjuvant chemotherapy for 2 - 4 cycles. Gastrectomy and D2 lymphadenectomy were given to patients after neoadjuvant chemotherapy. The efficacy was evaluated according RECIST 1.1 criteria. Efficacy was compared among patients with different platelet count before neoadjuvant chemotherapy. Results Twenty patients achieved complete response and 59 patients achieved partial response. 40 patients had stable disease, 3 patients suffered from progressive disease. The overall response rate was 64. 8% and disease control rate was 97.5%. The overall response rate of the 19 patients whose platelet count were more than 300 x 109/L was lower than those 103 patient whose platelet count was 〈300 x 10^9/L （36.8% vs. 69.9%, X2 =7.682,P =0.008）. Conclusions Higher Dlatelet count predicts Door resoonse to neoadiuvant chemotherapy in gastric cancer patients.
出处
《中华普通外科杂志》
CSCD
北大核心
2016年第7期593-595,共3页
Chinese Journal of General Surgery
基金
国家重点基础研究发展计划基金资助项目（2014CBA02002）
关键词
胃肿瘤
血小板
放化疗
辅助
Stomach neoplasms
Platelet
Chemoradiotherapy, adjuvant
